Sci Transl Med Cover Story: PeriCruiser® Platform by Yimufeng Bio Enables Safer CAR-T Therapy for Solid Tumors by Mitigating On-Target Off-Tumor Toxicity

Jan 27, 2025 10:11 CST Updated 10:11

Immunofoco

Developer of Novel Therapeutics for Solid Tumors

Click on the image to register for free2025 IBI EXPO

January 27, 2025

eMedClub News

CAR-T cell therapy has achieved remarkable success in the treatment of hematological tumors, but it still faces many challenges in solid tumors. Among them, the most prominent issue isOn-target Off-tumor ToxicitySince most of the targets for solid tumors are tumor-associated antigens (TAA), which are also expressed in normal tissues, CAR-T cells may mistakenly attack normal tissues, leading to severe toxic side effects.

To address this issue, Immunofoco, a Suzhou-based biotechnology company specializing in cell therapy for solid tumors, has collaborated with Professor Bo Zhai from Renji Hospital affiliated with Shanghai Jiao Tong University (currently the Director of the Minimally Invasive Interventional Treatment Center at Dongfang Hospital affiliated with Tongji University), and other teams to develop Peri Cruiser.^®Innovative technology platform, by adjusting the tissue distribution of CAR-T cells in the body,Significantly reduced the on-target off-tumor toxicity caused by the expression of tumor-associated antigens (TAA) in normal tissues.

This platform not only retains the ability of CAR-T to kill primary tumors but also effectively controls tumor metastasis.Provides a breakthrough solution for the application of CAR-T in solid tumor treatment. This research achievement was published on January 22 in a top academic journal.Science Translational Medicine, and featured as the cover article of that issue, marking an important breakthrough for the company in the field of solid tumor CAR-T cell therapy!

←Swipe left and right to view sub-forums→

Click the image to view the detailed schedule

Peri Cruiser^®Technology platform based onMultiple shRNA TechnologySimultaneously achieving CAR expression and knocking down the expression of multiple key T cell adhesion and migration molecules on a lentiviral vector can significantly reduce the toxicity of CAR-T cells in normal tissues. Study results show that this technology can significantly decrease CAR-T entry into normal tissues (e.g., liver and lung) while preserving the ability to infiltrate tumors.

Through various in vitro experiments, such as continuous killing assays, it was demonstrated that reducing the expression of adhesion molecules can enhance the sustained cytotoxic capacity of CAR-T cells against tumors, decrease the expression of exhaustion markers, and increase the proportion of memory cells. Meanwhile, it does not affect the formation of immunological synapses between CAR-T and tumor cells, showcasing the multiple advantages of this technical platform.

Researchers also conducted in vivo efficacy studies in colon cancer and gastric cancer models, Peri Cruiser^®The technical platform retains the ability to suppress various solid tumors and metastatic tumors, demonstrating overall good anti-tumor activity. This research not only presents a completely new CAR-T technology concept but also provides solutions for safer and more effective application of CAR-T therapy in solid tumors.

Dr. Sun Minmin, Founder, Chairman & CEO of Immunofoco, stated:

"Expanding the application of cell therapy in solid tumors is highly challenging, especially due to the potential off-tumor toxicity, which limits the selection of CAR-T targets and their application across various solid tumors. Immunofoco is a biotechnology company dedicated to breaking through the barriers to curing solid tumors and bringing long-term survival benefits to patients worldwide through the development of immune cell therapy drugs. Our PeriCruiser® technology platform provides an innovative solution to the bottleneck issues faced in expanding the use of CAR-T therapy in solid tumors. This achievement represents not only a significant milestone for the company’s technological platform but also demonstrates our solid progress toward realizing the vision of curing solid tumors. Moving forward, we will continue collaborating with medical experts to accelerate the translation of technology into clinical applications, always keeping patients at the center while promoting safer and more efficient immune cell therapies to benefit patients globally."

References:

1.https://mp.weixin.qq.com/s/kwtRJhPqnetL7Sp5GQYRAQ

Welcome everyone to register for the 2025 IBI EXPO conference and move forward with the times. Below is the 2024 IBI EXPO.Video Highlights of the Event.

Registration and Event Inquiry

IBI EXPO 2025 (3rd) Biopharmaceutical Innovation Industry ConferenceWill beMarch 1, 2025 to March 2, 2025InSuzhou International Expo CenterGrandly held. The theme of the conference isCollaboratively Building the Entire Chain, Innovating and Transforming the New Ecosystem。

The conference will invite300+Guest Speaker, Opening30+Forum activities, covering hundreds of hot topics, aroundCell and Gene Therapy, Radiopharmaceuticals, Antibody Innovation Conjugation, Targeted Protein Degradation, Stem Cell Regeneration, mRNA Vaccines and Nucleic Acid Drugs, Exosomesetc.New Molecular Drugs,AI Drug Discovery, Organoids, Novel Delivery Vectorsetc.Cutting-edge Technology，Engage in exchange and discussion, and collaboratePharmaceutical companies, research institutions, clinical resources, supply chain enterprises, investment and financing institutions, park governmentsThrough the joint efforts of multiple parties, cutting-edge innovations are being transformed from scientific research to industrial applications, injecting a source of development into the biopharmaceutical market.

Free Participation:Teacher Yang 15517201185

Free Exhibition:Teacher Yuan 15572286596

Speech & Media：Teacher Wang 18717836231

Click"Read the original text"Lock in Early Bird Discounts

Statement and Copyright Notice

Disclaimer: This article aims to convey industry development information and explore the frontier progress of biomedicine. The content of the article represents the author's viewpoint and does not represent the position of EMedClub, nor does it constitute any value judgment, investment advice, or medical guidance. If needed, please consult a professional for investment or visit a正规 hospital for medical advice.

Copyright Statement:Welcome to share the article on your personal WeChat Moments. Unauthorized reproduction by media or organizations in any form to other platforms is prohibited. For authorization, please leave a message below the article.

DianDian "Share”、“Like" and "In view"，Give me a little recharge~